{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:40:16Z","timestamp":1760236816299,"version":"build-2065373602"},"reference-count":8,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>An evaluation program for newborn screening for Severe Combined Immunodeficiency began in England in September 2021 based on TREC analysis. Flow cytometry is being used as the follow up diagnostic test for patients with low\/absent TRECS. The immunology laboratories have established a protocol and values for diagnosing SCID, other T lymphopenias and identifying healthy babies. This commentary describes the flow cytometry approach used in England to define SCID, T lymphopenia and normal infants after a low TREC result. It provides background to the flow cytometry assays being used and discusses the need to monitor and potentially change these values over time.<\/jats:p>","DOI":"10.3390\/ijns8010001","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:16:18Z","timestamp":1640254578000},"page":"1","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Flow Cytometry Confirmation Post Newborn Screening for SCID in England"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-3958","authenticated-orcid":false,"given":"Kimberly C.","family":"Gilmour","sequence":"first","affiliation":[{"name":"Immunology Laboratory, Camelia Botnar Laboratories, Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2010-08-300384","article-title":"Neonatal diagnossi of severe combined immunodefricney leads to significantly improved survival outcome: The case for newbron screening","volume":"17","author":"Brown","year":"2011","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Knight, V., Heimall, J.R., Wright, N., Dutmer, C.M., Boyce, T.G., Torgerson, T.R., and Abraham, R.S. (2020). Follow-up for an abnormal newborn screen for severe combined immunodeficiencies (nbs scid): A clinical immunology society (CIS) Survey of Cur\/1 rent Practices. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6030052"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e20182300","DOI":"10.1542\/peds.2018-2300","article-title":"Newborn screening for severe combined immunodeficiency and T-cell Lymphopenia in California, 2010\u20132017","volume":"143","author":"Amatuni","year":"2019","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3476(97)70200-2","article-title":"Immunophneotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations","volume":"130","author":"Neijens","year":"1997","journal-title":"J. Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2013.09.044","article-title":"Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The primary immune deficiency treatment consortium experience","volume":"133","author":"Shearer","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3389\/fimmu.2019.02406","article-title":"First Universal Screening Program for Severe Combined Immunodeficiency in Europe. Two years\u2019 experience in Catalonia (Spain)","volume":"10","author":"Colobran","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/cei.13062","article-title":"A comparison of TRECs and flow cytometry for na\u00efve T cell quantification","volume":"191","author":"Adams","year":"2018","journal-title":"Clin. Exp. Immunol."}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/8\/1\/1\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:52:24Z","timestamp":1760169144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/8\/1\/1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijns8010001"],"URL":"https:\/\/doi.org\/10.3390\/ijns8010001","relation":{},"ISSN":["2409-515X"],"issn-type":[{"type":"electronic","value":"2409-515X"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}